ArticleMedicine2026
The triglyceride-glucose index as a surrogate marker of insulin resistance for predicting peripheral vascular complications in patients with type 2 diabetes: A retrospective analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The TyG index, a simple surrogate marker for insulin resistance, shows promise for predicting vascular complications in T2DM. This study evaluated its utility in predicting peripheral vascular complications and analyzed the dose-response relationship. A retrospective analysis included 186 T2DM patients admitted between April and December 2025. Participants were categorized into a complications group (n = 66) and a no-complications group (n = 120). The TyG index was calculated and divided into quartiles. Multivariate logistic regression identified risk factors. RCS curves assessed the dose-response relationship, and ROC curves evaluated predictive value. The complications group was significantly older with longer diabetes duration. They exhibited higher fasting glucose, triglycerides, TyG index, cystatin C, urea, and creatinine levels (all P < .05), but lower HDL-C, albumin, eGFR, and hemoglobin levels (all P < .05). Prevalence of peripheral vascular disease increased progressively across TyG quartiles (Q1: 8.7%, Q2: 23.9%, Q3: 41.3%, Q4: 68.1%; P < .001). Multivariate analysis, using Q1 as reference, showed significantly elevated risks for complications: Q2 (OR = 2.24, 95% CI: 1.02-1.58, P = .046), Q3 (OR = 2.89, 95% CI: 1.34-4.31, P < .001), and Q4 (OR = 4.47, 95% CI: 2.42-6.58, P < .001). RCS analysis confirmed a significant nonlinear positive correlation between TyG index and complication risk (P for nonlinearity < .001). ROC analysis demonstrated the TyG index predicted complications with an AUC of 0.768 (95% CI: 0.698-0.838). The optimal cutoff value was 8.89, yielding 75.8% sensitivity and 70.8% specificity. The TyG index exhibits a significant nonlinear positive cross-sectional association with peripheral vascular complications in T2DM patients. While these findings suggest the potential utility of the TyG index as a marker for identifying existing peripheral vascular complications, larger multicenter prospective studies with external validation are needed before clinical implementation can be recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.